Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbidol post-exposure prophylaxis study in high-risk populations exposed to COVID-19
ChiCTR2000029592Phase 4Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of umifenovir in coronavirus disease 2019 (COVID-19) (2 cohorts), sponsored by Union Hospital. Primary endpoints: 2019-nCoV RNA, 2019-nCoV antibody and 1 more. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
umifenovir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000029592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029592.